Fresenius Medical Care AG & Co. KGaA Q2 FY2025 earnings call

Helen Giza noted second quarter results reflected continued improvement in operational performance with 7% organic revenue growth, 13% operating income growth, 75% operating cash flow increase, and net leverage ratio at 2.7x within target range. The FME25+ transformation delivered EUR 58 million in savings towards the EUR 180 million target. Segment developments included Care Delivery having mixed U.S. volume with accelerated inflows but higher outflows from flu season, Value-Based Care as a separate segment showing strong revenue growth but operating loss, and Care Enablement continuing margin progress and 5008x launch on track. The company is preparing for FME Reignite strategy outlined at Capital Markets Day, focusing on patient care and innovation.

In the second quarter, Fresenius Medical Care delivered strong organic revenue growth of 7% with positive contributions from all 3 operating segments. Care Delivery had organic revenue growth of 3.6%, with U.S. organic growth 3.4% driven by rate and payer mix, offsetting flu season volume impact, and international organic growth 4.5% from 1.7% same-market treatment growth and rate increases; operating income margin expanded to 11.2%. Value-Based Care realized strong organic revenue growth of 28% in Q2, driven by higher member months from contract expansion, but operating income was a loss of EUR 9 million due to unfavorable savings rate and inflation. Care Enablement had strong revenue growth of 3%, organic growth 3%, with operating income increasing 79% and margin at 8.7% within the 2025 target band of 8%-12%.

Fresenius Medical Care confirmed its full year 2025 outlook. Expected strong revenue growth in Value-Based Care at the upper end of the positive to low single-digit percent range. Operating income is expected to grow in the high teens to high 20s percent. The full year operating income guidance range is confirmed, including the upper end. The company initiated a share buyback program of EUR 1 billion, with the first tranche planned in August.

Higher-than-expected patient outflows due to severe flu season in the U.S. impacted volume growth assumptions. Elevated mortality from the flu season carried forward dampening volume growth in subsequent quarters. Unfavorable foreign exchange rates had a negative impact on financials, with an expected 3%-4% impact on revenue and earnings if exchange rates stay volatile.

Q: On U.S. volume growth and 2026 outlook, and Care Enablement margin A: Helen Giza stated U.S. volume is expected to be flat to slightly positive in the back half, encouraged by improving inflow trends. For Care Enablement, the margin is expected to be stronger in the second half within the 8%-12% band.

Q: Patient inflow dynamics, mortality quantification, and Value-Based Care progress A: Helen Giza mentioned improving patient inflows but elevated mortality from the flu season. Value-Based Care has strong revenue growth but the operating margin remains slightly negative to neutral, with more transparency on KPIs expected as the segment matures.

Q: Impact of softer volume on H2 expectations and Value-Based Care incremental revenue A: Helen Giza said the softer volume has limited impact on the second half of the year. Value-Based Care had EUR 200 million in incremental revenue in the first half and is expected to have more than EUR 1.9 billion in incremental revenue for the full year.

Q: Mortality, missed treatments, and Value-Based Care KPIs A: Helen Giza noted that mortality and missed treatments from the flu season are still elevated. Value-Based Care will provide more transparency on key performance indicators as it becomes more mature.

Q: Guidance levers and capital allocation with lower volumes A: Helen Giza explained that the guidance range is dependent on balancing headwinds and tailwinds. Martin Fischer noted that capital allocation prioritizes investment in the core with a share buyback program planned.

Q: 2026 headwinds, phosphate binders, ACA subsidies, and ProKidney clinical data A: Helen Giza said 2026 guidance is not provided yet, and ProKidney clinical data impact on CKD progression is awaited. On phosphate binders and ACA subsidies, detailed 2026 outlook will be provided later.

Q: HDF machine rollout and FX headwind A: Helen Giza said the HDF machine rollout in the U.S. will start in Q3 with 30 clinics and 600 machines converted. FX is expected to have a 3%-4% impact on revenue and earnings if exchange rates stay volatile.